^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    SSTR2 modulator

    Related drugs:
    Apply
    Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) (NCT04086485)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/03/2022
    Primary completion :
    07/01/2025
    Completion :
    01/01/2026
    BRCA • SSTR
    |
    SSTR positive
    |
    Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)
    Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors (NCT04750954)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    07/22/2021
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    SSTR
    |
    SSTR Expression
    |
    peposertib (M3814) • Lutathera (lutetium Lu 177 dotatate)
    Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (NCT04665739)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    02/03/2023
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    SSTR
    |
    cisplatin • everolimus • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)
    177Lutetium-DOTATATE in Children with Primary Refractory or Relapsed High-risk Neuroblastoma (LuDO-N) (NCT04903899)
    Phase 2
    Jakob Stenman
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    05/19/2021
    Primary completion :
    05/20/2026
    Completion :
    05/20/2031
    SSTR • CD34 • SSTR2
    |
    SSTR2 expression • SSTR Expression
    |
    Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)
    Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET (ReLUTH) (NCT04954820)
    Phase 2
    Institut du Cancer de Montpellier - Val d'Aurelle
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/18/2021
    Primary completion :
    10/01/2031
    Completion :
    10/01/2031
    SSTR
    |
    Lutathera (lutetium Lu 177 dotatate)
    Using Novel Imaging to More Safely Treat Neuroendocrine Tumors (NCT06122610)
    Phase 1
    University of Wisconsin, Madison
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    02/01/2025
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    SSTR
    |
    SSTR positive
    |
    Lutathera (lutetium Lu 177 dotatate)
    Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma (NCT03206060)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    10/10/2017
    Primary completion :
    01/01/2026
    Completion :
    01/01/2027
    NF1 • VHL • SSTR
    |
    RET mutation • VHL mutation
    |
    Lutathera (lutetium Lu 177 dotatate)
    Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (NCT05691465)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    12/27/2023
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    TP53 • PTEN • RB1 • SYP • CHGA
    |
    Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)
    177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer (NCT04529044)
    Phase 2
    OHSU Knight Cancer Institute
    Not yet recruiting
    Last update posted :
    12/20/2024
    Initiation :
    01/01/2025
    Primary completion :
    12/20/2025
    Completion :
    12/20/2025
    PD-L1 • CDK4 • SSTR
    |
    Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)
    Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery (NCT04609592)
    Phase 1
    Stanford University
    Recruiting
    Last update posted :
    10/28/2024
    Initiation :
    03/17/2021
    Primary completion :
    03/01/2025
    Completion :
    09/01/2027
    SSTR
    |
    PGR expression
    |
    Lutathera (lutetium Lu 177 dotatate)
    Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases (NELMAS) (NCT05987176)
    Phase 2
    Imperial College London
    Recruiting
    Last update posted :
    08/09/2024
    Initiation :
    08/02/2024
    Primary completion :
    09/01/2028
    Completion :
    03/30/2029
    SSTR
    |
    Lutathera (lutetium Lu 177 dotatate)
    Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients (ALPHAMEDIX02) (NCT05153772)
    Phase 2
    Radiomedix, Inc.
    Active, not recruiting
    Last update posted :
    05/27/2024
    Initiation :
    12/21/2021
    Primary completion :
    10/01/2026
    Completion :
    10/01/2026
    SSTR
    |
    AlphaMedix (ORM-2110)
    Lutathera and ASTX727 in Neuroendocrine Tumours (LANTana) (NCT05178693)
    Phase 1
    Imperial College London
    Recruiting
    Last update posted :
    03/20/2024
    Initiation :
    04/25/2022
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    SSTR2
    |
    SSTR2 expression
    |
    Inqovi (decitabine/cedazuridine) • Lutathera (lutetium Lu 177 dotatate)
    177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (LuPARP) (NCT04375267)
    Phase 1
    Vastra Gotaland Region
    Active, not recruiting
    Last update posted :
    11/14/2023
    Initiation :
    04/23/2020
    Primary completion :
    06/30/2024
    Completion :
    06/30/2024
    SSTR
    |
    SSTR positive
    |
    Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)
    Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET (ALPHAMEDIX01) (NCT03466216)
    Phase 1
    Radiomedix, Inc.
    Recruiting
    Last update posted :
    08/24/2021
    Initiation :
    02/05/2018
    Primary completion :
    07/01/2022
    Completion :
    07/01/2022
    SSTR
    |
    AlphaMedix (ORM-2110)
    Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy (CHARRT) (NCT04039516)
    Phase 2
    King's College Hospital NHS Trust
    Not yet recruiting
    Last update posted :
    08/04/2020
    Initiation :
    10/01/2020
    Primary completion :
    11/01/2024
    Completion :
    12/01/2024
    SSTR
    |
    Lutathera (lutetium Lu 177 dotatate)